Propofol is an anesthetic agent suspended in an emulsion system that includes egg yolk lecithin and soybean oil, because of which, there is concern about the use of propofol in patients allergic to these substances. We examined the association between propofol administration and incidence of adverse events in dogs with allergy to egg yolk lecithin and soybean oil. On the basis of the findings of an allergen-specific immunoglobulin E (IgE) test, 14 dogs with high levels (high-IgE group) and 7 dogs with low levels (normal-IgE group) of IgE were selected. Following intravenous administration of propofol, the incidence of anaphylactic reactions and plasma histamine concentrations under general anesthesia maintained with isoflurane throughout surgery were compared between the two groups. The frequency of anaphylactic reactions and plasma histamine concentrations were compared by the chi-square test and Student t-test, respectively. The statistical significance for both tests was set at P<0.05. In the high- and normal-IgE groups, the average frequencies of anaphylactic reactions after propofol administration were 21.4 and 14.3%, and the mean plasma histamine concentrations were 167.9 ± 94.5 nM and 65.7 ± 40.3 nM, respectively. Animals of neither groups experienced shock-like symptoms. These results revealed that propofol might be relatively safe, although careful perioperative anesthesia monitoring and standby protocols are required when using propofol in dogs with a history of allergic diseases or high chicken- or soybean-specific IgE levels.
1 January 2017 in Journal of Veterinary Medical Science
The outcomes of cardiopulmonary resuscitation (CPR) were retrospectively evaluated in 146 exotic animals including 20 pet birds, 47 rabbits, 34 hamsters, 18 ferrets, 7 turtles and 20 other small mammals in cardiopulmonary arrest (CPA) at presentation or during hospitalization at an animal clinic. The rates of return of spontaneous circulation, survival after CPR and discharge were 9.3, 2.3 and 1.2%, respectively. The mean success rate of CPR in animals included in this study was lower than those previously reported in dogs and cats. This might have been because of the challenges in effective chest compression, airway management and monitoring as well as establishment of intravenous catheterization route in exotic animals.
Background: Overall survival is the most important outcome for treatment response in feline chronic kidney disease (CKD). Beraprost has been shown to reduce the kidney function decline in cats with International Renal Interest Society (IRIS) stage 2 and 3 CKD. However, the association with prolonged survival has not yet been examined. Objective: To assess the relationship between beraprost and overall survival in cats with CKD in real clinical practice. Animals: Client-owned cats with IRIS stage 3 CKD (n = 134) were evaluated between 2017 and 2020. Methods: A retrospective cohort study based on data from electronic medical records of one hospital. Results: The cohort was divided into “beraprost therapy” and “no beraprost therapy” groups, and survival analyses revealed that overall survival was significantly longer in the beraprost therapy group, using Kaplan–Meier curves (p = 0.004). However, baseline phosphate is known to be an important prognostic indicator and was not well balanced between the two groups. Therefore, a subcohort of 97 cats was selected (those having baseline phosphate <6.0 mg/dL) that allowed for this parameter to be balanced between groups. The survival data in this subcohort were consistent with those of the overall study cohort. Conclusions: In feline patients with CKD, beraprost therapy is associated with better overall survival.
Kangaroo disease (lumpy jaw disease; LJD) is a disease of the oral cavity in Macropodidae that may be caused by stress-related factors; however, detailed information about its pathogenesis is lacking. Therefore, in this study, we evaluated markers of stress in kangaroos with and without LJD to determine the factors that cause an LJD outbreak. We evaluated the oxidative stress value, antioxidant activity, and plasma cortisol concentration in blood samples. Additionally, we measured the cortisol concentration in saliva samples. The oxidative stress value and serum cortisol concentrations were statistically significantly different between the two groups, but the antioxidant activity and saliva cortisol concentrations did not differ significantly. Relatively large variations were observed for each value within individuals.
In acidosis, catecholamines are attenuated and higher doses are often required to improve cardiovascular function. Colforsin activates adenylate cyclase in cardiomyocytes without mediating the beta adrenoceptor. In this study, six beagles were administered either colforsin or dobutamine four times during eucapnia (partial pressure of arterial carbon dioxide 35-40 mm Hg; normal) and hypercapnia (ibid 90-110 mm Hg; acidosis) conditions. The latter was induced by carbon dioxide inhalation. Anesthesia was induced with propofol and maintained with isoflurane. Cardiovascular function was measured by thermodilution and a Swan-Ganz catheter. Cardiac output, heart rate, and systemic vascular resistance were determined at baseline and 60 min after 0.3 μg/kg/min (low), 0.6 μg/kg/min (middle), and 1.2 μg/kg/min (high) colforsin administration. The median pH was 7.38 [range 7.34–7.42] and 7.04 [range 7.01–7.08] at baseline in the Normal and Acidosis conditions, respectively. Endogenous adrenaline and noradrenaline levels at baseline were significantly (P< 0.05) higher in the Acidosis than in the Normal condition. Colforsin induced cardiovascular effects similar to those caused by dobutamine. Colforsin increased cardiac output in the Normal condition (baseline: 198.8 mL/kg/min [range 119.6–240.9], low: 210.8 mL/kg/min [range 171.9–362.6], middle: 313.8 mL/kg/min [range 231.2–473.2], high: 441.4 mL/kg/min [range 373.9–509.3];P< 0.001) and the Acidosis condition (baseline: 285.0 mL/kg/min [range 195.9–355.0], low: 297.4 mL/kg/min [213.3–340.6], middle: 336.3 mL/kg/min [291.3–414.5], high: 366.7 mL/kg/min [339.7–455.7] ml/kg/min;P< 0.001). Colforsin significantly increased heart rate (P< 0.05 in both conditions) and decreased systemic vascular resistance (P< 0.05 in both conditions) compared to values at baseline. Systemic vascular resistance was lower in the Acidosis than in the Normal condition (P< 0.001). Dobutamine increased pulmonary artery pressure, whereas colforsin did not. Colforsin offsets the effects of endogenous catecholamines and may not increase cardiac output during hypercapnia.
Chronic kidney disease (CKD) in dogs is a progressive condition with a poor prognosis and a lack of effective pharmacological interventions to extend survival. Beraprost, an oral prostacyclin analog approved for feline CKD, was off-label prescribed and evaluated for its effect on survival in dogs with naturally occurring IRIS stage 2 CKD. This prospective clinical study included a treatment group ( n = 16) receiving oral beraprost (12.5 μg/kg twice daily), and a well-matched historical control group ( n = 17) from the same institution. The primary outcome, overall survival, was analyzed using the Kaplan-Meier method and a multivariable Cox proportional hazards model. Baseline characteristics were largely comparable between the groups. Significantly longer survival was observed in the beraprost-treated group, with a median survival time of 1,101 days (a 5.6-fold increase), compared to 198 days in the control group ( P = 0.001). Furthermore, beraprost therapy was associated with a significant delay in the time to secondary composite endpoints, including disease progression (to IRIS stage 3/4) or death ( P = 0.001) and 10% body weight loss or death ( P = 0.028), underscoring the robustness of the survival data. After adjusting for age and urine protein-to-creatinine ratio, beraprost treatment remained the sole independent predictor of improved survival (hazard ratio, 0.15; 95% confidence interval 0.03–0.79; P = 0.025). Although limited by its non-randomized design and small sample size, this study provides the first clinical evidence that oral beraprost is associated with a substantial benefit on overall survival in dogs with IRIS stage 2 CKD, supporting the need for large-scale randomized controlled trials.